An open-label, multi-center, long-term extension study to evaluate the safety and tolerability of oral tesaglitazar 0.5mg when addded to insulin therapy in patients with type 2 diabetes mellitus (GALLEX 9)

Trial Profile

An open-label, multi-center, long-term extension study to evaluate the safety and tolerability of oral tesaglitazar 0.5mg when addded to insulin therapy in patients with type 2 diabetes mellitus (GALLEX 9)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2010

At a glance

  • Drugs Tesaglitazar (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms GALLEX-9
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Nov 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 18 Nov 2010 Last checked against ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top